Neurocrine Biosciences (NBIX) said late Monday its phase 2 study evaluating the efficacy, safety and tolerability of experimental drug, NBI-1070770, in adults with major depressive disorder did not meet the primary endpoint compared with placebo.
The drug developer said the phase 2 study enrolled 73 adult patients with a diagnosis of major depressive disorder with inadequate response to at least one antidepressant in their current episode of treatment.
Neurocrine said it acquired rights to develop and market the experimental drug from Takeda Pharmaceutical (TAK).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments